TEXT-Fitch affirms St. Jude Children's Research Hospital, Tenn. at 'AAA'

Wed Jan 30, 2013 5:20pm EST

Related Topics

Jan 30 - Fitch Ratings has affirmed the 'AAA' rating on the approximately
$234 million Shelby County Health, Educational, and Housing Facility Board,
Tennessee revenue bonds, series 2006 issued on behalf of St. Jude Children's
Research Hospital (St. Jude).

This is the only debt outstanding and is 100% fixed rate. The Rating Outlook is
Stable.

SECURITY
The bonds are secured by an unrestricted revenue pledge of the hospital and an
unconditional guaranty by the American Lebanese Syrian Associated Charities
(ALSAC). Under the guaranty agreement, ALSAC has guaranteed the full and prompt
payment of the series 2006 bonds.

SENSITIVITIES/RATING DRIVERS

REPUTATION AND BRAND RECOGNITION: St. Jude is one of the world's premier centers
for research and treatment of catastrophic diseases in children. Through ongoing
support from its affiliated organization, ALSAC, St. Jude provides care,
treatment and support services at no cost to families.

IMPRESSIVE FUNDRAISING RECORD: All funds raised by ALSAC are for the sole
benefit of St. Jude. ALSAC was started by Danny Thomas and its total endowment
has grown to $2.4 billion. Annual fundraising has increased every year through
the current depressed economic environment with unrestricted contributions and
support of $797 million in fiscal 2012 (June 30 year end).

OVERALL STRONG FINANCIAL PROFILE: St. Jude/ALSAC's financial profile is
characterized by very strong liquidity and low debt burden with 695 days cash on
hand, 6.8x unrestricted cash to debt, and 14x debt service coverage in fiscal
2012.

CREDIT PROFILE
The rating affirmation reflects St. Jude's reputation and brand recognition,
which has led to strong fundraising activity by ALSAC. The bylaws of ALSAC
require that all funds raised (except for funds required for operations and
restricted by donor) be distributed to or be held for the exclusive benefit of
St. Jude.

ALSAC has had very strong fundraising success, raising $691.9 million in fiscal
2010, $735.2 million in fiscal 2011, and $813.6 million in fiscal 2012. The
target for fiscal 2013 is $832 million. The vast majority of donors are
individuals through its national direct marketing efforts (television and mail).
ALSAC's fundraising goal is to increase the amount raised 3%-5% every year over
the next five years.

St. Jude and ALSAC are integral to each other's success and strategic planning
is done jointly. ALSAC sets an annual fundraising target every year based on the
hospital's projected need. In 2012, ALSAC provided approximately 69% of St.
Jude's $640.2 million total revenue. St. Jude's and ALSAC's total combined
unrestricted revenue in fiscal 2012 was $979 million and included $797 million
of contributions and bequests, $96 million of net patient revenue, and $95
million in research grants. The remaining revenue sources include net investment
losses and other revenue.

St. Jude/ALSAC's financial profile is strong with ample coverage and cushion
provided by its financial resources relative to debt and operations. ALSAC had
$2.4 billion in total investments as of Dec. 31 2012, which was invested in
35.6% equities, 24.6% hedge funds, 7.6% private investments, 15.9% real assets,
1.6% multi asset managers and 14.7% cash and fixed income. The portfolio is
diverse and ALSAC has not changed its investment policy. The liquidity of the
portfolio is also good with over 50% available within three months, 77% within
six months and 80% within one year.

The Stable Outlook reflects the expectation that St. Jude/ALSAC will continue to
produce excellent financial results as the result of its strong fundraising
abilities.

St. Jude conducts research and treatment for childhood cancers and diseases and
treats patients regardless of their ability to pay. The hospital provides
inpatient and outpatient services to approximately 5,700 active patients every
year. Patients are accepted based on their eligibility to enroll in clinical
research protocols. St. Jude has entered into the second phase of its pediatric
genome project in conjunction with Washington University School of Medicine in
St. Louis to decode the genomes of more than 600 childhood cancer patients.
There are no other major capital projects on the horizon beyond what is
currently under construction. Tower II, which will replace St. Jude's intensive
care unit and operating rooms is expected to be complete in fiscal 2014. St.
Jude will also add proton beam therapy by fiscal 2016. The cost of these
projects total approximately $200 million. There are no additional debt plans.

St. Jude is a 78-licensed bed pediatric specialty hospital and research
organization (with associated outpatient clinics and other facilities). St. Jude
is located in Memphis, Tennessee and is the only NCI designated cancer center
devoted solely to children. St. Jude/ALSAC posts its audited annual financial
statements and unaudited quarterly financial statements to the Nationally
Recognized Municipal Securities Information Repositories.

Additional information is available at 'www.fitchratings.com'. The ratings above
were solicited by, or on behalf of, the issuer, and therefore, Fitch has been
compensated for the provision of the ratings.

Applicable Criteria and Related Research:
'Revenue-Supported Rating Criteria', dated June 12, 2012
'Nonprofit Institutions Rating Criteria', dated June 15, 2012
'Fitch Upgrades St. Jude Children's Research Hospital's (Tennessee) Bonds to
'AAA'' , dated Feb 14, 2011

Applicable Criteria and Related Research:
Revenue-Supported Rating Criteria
Nonprofit Institutions Rating Criteria
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.